Net product sales — Contract with Customer, Liability
Moderna Net product sales — Contract with Customer, Liability decreased by 11.2% to $95M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 38.3%, from $154M to $95M. Over 4 years (FY 2021 to FY 2025), Net product sales — Contract with Customer, Liability shows a downward trend with a -61.9% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
A rising balance suggests increasing uncertainty in revenue realization or higher expected future costs related to current sales contracts.
Detailed definition
This represents the total outstanding liability balance related to customer contracts, including provisions for variable...
Peer comparison
Comparable to 'accrued rebates and returns' or 'deferred revenue' liabilities found in the balance sheets of commercial-stage biotech companies.
mrna_segment_net_product_sales_contract_with_customer_liabilityHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.24B | $8.3B | $6.7B | $5.9B | $4.33B | $4.1B | $2.63B | $1.82B | $1.7B | $1.5B | $613M | $580M | $740M | $443M | $188M | $154M | $221M | $144M | $107M | $95M |
| QoQ Change | — | +14.7% | -19.3% | -11.9% | -26.7% | -5.2% | -36.0% | -30.8% | -6.4% | -11.8% | -59.1% | -5.4% | +27.6% | -40.1% | -57.6% | -18.1% | +43.5% | -34.8% | -25.7% | -11.2% |
| YoY Change | — | — | — | — | -40.2% | -50.6% | -60.8% | -69.2% | -60.7% | -63.4% | -76.7% | -68.1% | -56.5% | -70.5% | -69.3% | -73.4% | -70.1% | -67.5% | -43.1% | -38.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Moderna's net product sales — contract with customer, liability?
- Moderna (MRNA) reported net product sales — contract with customer, liability of $95M in Q1 2026.
- How has Moderna's net product sales — contract with customer, liability changed year-over-year?
- Moderna's net product sales — contract with customer, liability decreased by 38.3% year-over-year, from $154M to $95M.
- What is the long-term trend for Moderna's net product sales — contract with customer, liability?
- Over 4 years (2021 to 2025), Moderna's net product sales — contract with customer, liability has grown at a -61.9% compound annual growth rate (CAGR), from $29.71B to $626M.
- What does net product sales — contract with customer, liability mean?
- The total amount of revenue set aside to cover future discounts, rebates, and potential product returns.